scPharmaceuticals Inc. Announces Nasdaq Delisting and SEC Deregistration Following Merger Completion

Reuters10-07
scPharmaceuticals Inc. Announces Nasdaq Delisting and SEC Deregistration Following Merger Completion

**scPharmaceuticals Inc. Announces Nasdaq Delisting Following Merger** scPharmaceuticals Inc. has announced that, following the completion of a merger, it will delist its shares from the Nasdaq Global Select Market. Trading of the company's shares was halted prior to the market opening on October 7, 2025. Nasdaq is expected to file Form 25 with the SEC on the same date to remove scPharmaceuticals' shares from listing and registration. The company also plans to file Form 15 with the SEC to terminate its registration and suspend its reporting obligations under the Securities Exchange Act. These moves are part of the company's transition following the closing of the merger.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. scPharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-232754), on October 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment